| 1 |
22868830 | Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. | 2013 Jun |
1 |
| 2 |
21198716 | An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. | 2011 Feb |
1 |
| 3 |
22087859 | Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. | 2011 Nov 16 |
1 |
| 4 |
20415685 | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | 2010 May |
1 |
| 5 |
18951999 | Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant. | 2009 Feb |
1 |
| 6 |
19112166 | Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. | 2009 Mar |
1 |
| 7 |
19199981 | Pleiotropic effects of rimonabant: clinical implications. | 2009 |
1 |
| 8 |
18426513 | CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. | 2008 May |
1 |
| 9 |
18542014 | Inhibitors of cannabinoid receptors and glucose metabolism. | 2008 Jul |
1 |
| 10 |
17296341 | Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. | 2007 Feb |
1 |
| 11 |
17392496 | The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. | 2007 May |
1 |
| 12 |
18154742 | Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. | 2007 Dec 17 |
1 |
| 13 |
17208662 | The relation of adipose tissue to cardiometabolic risk. | 2006 |
1 |
| 14 |
16291982 | Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. | 2005 Nov 17 |
1 |